Vertex Pharmaceuticals INC / Ma Form 4 insider transactions

Vertex Pharmaceuticals director Suketu Upadhyay acquired 86.825 deferred stock units, increasing his beneficial ownership to 2,638.332 units.

Vertex Pharmaceuticals Director Bruce I. Sachs acquired 115.766 deferred stock units, increasing his beneficial ownership to 15,457.433 units.

Vertex Pharmaceuticals' EVP and Chief Legal Officer, Jonathan Biller, reported the sale of company common stock, including shares withheld for tax purposes, under a pre-arranged trading plan.

Vertex Pharmaceuticals director Sangeeta N. Bhatia sold 266 shares of common stock for $386.69 per share under a Rule 10b5-1 trading plan.

Vertex Pharmaceuticals CEO Reshma Kewalramani purchased 10,000 shares of company common stock for approximately $3.9 million through open market transactions.

A director at Vertex Pharmaceuticals acquired 5,000 shares of common stock through open market purchases totaling approximately $1.95 million.

Vertex Pharmaceuticals Director Suketu Upadhyay acquired 75.904 deferred stock units, increasing his beneficial ownership to 2,551.507 units.

Vertex Pharmaceuticals director Bruce I. Sachs acquired 101.206 deferred stock units, increasing his beneficial ownership and aligning his interests with shareholders.

Stuart A. Arbuckle, Executive Vice President and Chief Operating Officer of Vertex Pharmaceuticals Inc., disposed of 37,243 shares of common stock to satisfy tax withholding obligations.

David Altshuler, EVP and Chief Scientific Officer of Vertex Pharmaceuticals, reports the sale of 52 shares of common stock at a price of $424.69 per share.

Stuart A. Arbuckle, EVP and COO of Vertex Pharmaceuticals, reports the acquisition of 37,622 shares of common stock and disposal of 140 shares due to performance stock unit vesting.

Director Suketu Upadhyay reports acquisition and disposition of Vertex Pharmaceuticals stock and deferred stock units.

Director Nancy Thornberry reports acquisition of Vertex Pharmaceuticals common stock and stock options.

Director Jennifer Schneider reports acquisition of restricted stock units and disposal of common stock on May 1, 2025.

Bruce I. Sachs, a director of Vertex Pharmaceuticals, acquired 2,398 shares of common stock through the exercise of a stock option on May 1, 2025.

Director Diana McKenzie reports acquisition and disposition of Vertex Pharmaceuticals common stock and deferred stock units on May 1, 2025.

Michel Lagarde, a director at Vertex Pharmaceuticals, acquired 2,398 stock options on May 1, 2025, exercisable until April 30, 2035.

Director Alan Garber reports acquisition of common stock and exercise of stock options in Vertex Pharmaceuticals.

Director Lloyd Carney reports acquiring 796 shares of Vertex Pharmaceuticals common stock and disposing of 7,115 shares on May 1, 2025.

Director Sangeeta N. Bhatia reports acquisition of 796 shares of Vertex Pharmaceuticals common stock and disposition of 400 shares under a pre-arranged trading plan.

Director Suketu Upadhyay acquired deferred stock units convertible to common stock in Vertex Pharmaceuticals.

Bruce I. Sachs, a director at Vertex Pharmaceuticals, acquired deferred stock units representing 95.475 shares of common stock on April 15, 2025.

David Altshuler, EVP and Chief Scientific Officer of Vertex Pharmaceuticals, sold 3,231 shares of common stock at $510 per share on March 13, 2025, under a pre-arranged 10b5-1 trading plan.

Charles F. Wagner Jr., EVP & Chief Financial Officer of Vertex Pharmaceuticals, sold 3,298 shares of common stock at $500 per share on March 10, 2025, under a pre-arranged trading plan.

Ourania Tatsis, EVP, Chief Regulatory & Quality Officer of Vertex Pharmaceuticals, sold 3,242 shares of common stock at $499.99 per share on March 10, 2025, under a pre-arranged 10b5-1 trading plan.

David Altshuler, EVP and Chief Scientific Officer of Vertex Pharmaceuticals, reports the sale of 3,231 shares of common stock at $500 per share on March 10, 2025, according to a Form 4 filing.

Ourania Tatsis, EVP, Chief Regulatory & Quality Officer of Vertex Pharmaceuticals, sold 4,058 shares of common stock at $485.49 per share on March 4, 2025, under a pre-arranged trading plan.

David Altshuler, EVP and Chief Scientific Officer of Vertex Pharmaceuticals, reports the sale of 3,231 shares of common stock at $490 per share on March 3, 2025, under a pre-arranged trading plan.

Charles F Wagner Jr., EVP & Chief Financial Officer of Vertex Pharmaceuticals, disposed of 4,962 shares of common stock on February 26, 2025, to cover tax obligations.

Ourania Tatsis, EVP, Chief Regulatory & Quality Officer at Vertex Pharmaceuticals, reports the disposition and acquisition of company stock.